This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-05 and is reviewed periodically as new material appears.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
This distinction is particularly relevant in structural biology, materials science, and computational chemistry, where hydrogen bonding spans a continuum from weak van der Waals-like interactions to nearly covalent bonding. Hydrogen bonding can occur between separate molecules (intermolecular) or within different parts of the same molecule (intramolecular). Its strength varies considerably, depending on geometry, environment, and the donor-acceptor pair, typically ranging from 4.2 to 167.4 kJ/mol (1 to 40 kcal/mol). This places hydrogen bonds stronger than van der Waals interactions but generally weaker than covalent or ionic bonds. Hydrogen bonding plays a fundamental role in chemistry, biology, and materials science. It is responsible for the anomalously high boiling point of water, the stabilization of protein and nucleic acid structures, and key properties of materials like paper, wool, and hydrogels. In biological systems, hydrogen bonds mediate molecular recognition, enzyme catalysis, and DNA replication, while in materials science, they contribute to self-assembly, adhesion, and supramolecular organization.
Sulfamethoxazole (SMZ or SMX) is an antibiotic. It is used for bacterial infections such as urinary tract infections, bronchitis, and prostatitis and is effective against both gram negative and positive bacteria such as Escherichia coli and Listeria monocytogenes. Common side effects include nausea, vomiting, loss of appetite, and skin rashes. It is a sulfonamide and bacteriostatic. It resembles a component of folic acid. It prevents folic acid synthesis in the bacteria that must synthesize their own folic acid. Mammalian cells, and some bacteria, do not synthesize but require preformed folic acid (vitamin B9); they are therefore insensitive to sulfamethoxazole. It was introduced to the United States in 1961. It is now mostly used in combination with trimethoprim (abbreviated SMX-TMP). The SMX-TMP combination is on the WHO Model List of Essential medicines as a first-choice treatment for urinary tract infections. Other names include: sulfamethalazole and sulfisomezole.
=== Production of peptide and protein pharmaceuticals === Most protein pharmaceuticals are now produced through recombinant DNA technology using expression vectors. These peptide and protein pharmaceuticals may be hormones, vaccines, antibiotics, antibodies, and enzymes. The first human recombinant protein used for disease management, insulin, was introduced in 1982. Biotechnology allows these peptide and protein pharmaceuticals, some of which were previously rare or difficult to obtain, to be produced in large quantity. It also reduces the risks of contaminants such as host viruses, toxins and prions. Examples from the past include prion contamination in growth hormone extracted from pituitary glands harvested from human cadavers, which caused Creutzfeldt–Jakob disease in patients receiving treatment for dwarfism, and viral contaminants in clotting factor VIII isolated from human blood that resulted in the transmission of viral diseases such as hepatitis and AIDS. Such risk is reduced or removed completely when the proteins are produced in non-human host cells.
==== Electoral environment ==== According to Gallup, most factors with respect to the electoral environment favored Republicans and Trump. These included low confidence in the economy, Republicans outnumbering Democrats in party affiliation (48–45%), low national satisfaction, Republicans being favored to address the economy and immigration, and Biden's low job approval rating. Harris was viewed more favorably on character and had an advantage on some issues. No incumbent party has won when a president had below a 45% approval rating, either losing reelection (Jimmy Carter in 1980, George H. W. Bush in 1992, and Trump himself in 2020) or the incumbent party lost the White House (Hubert Humphrey in 1968). According to exit polls, voters disapproved of Biden's performance 59–39%, and disapproved of how things were going in the United States 73–25%. Also, voters judged the economy negatively 68–32%, and said that inflation had caused them hardship 75–24%. A YouGov poll conducted from November 6–7, 2024 found that if Biden had been the Democratic nominee, Trump would have won the popular vote 49–42%. Nonpartisan election forecasters, including The Cook Political Report and Sabato's Crystal Ball, stated before the election that Biden would have been almost certain to lose. Harris did improve compared to Biden among voters making over $100,000 a year. NBC News found that Trump made larger gains in counties with tougher housing markets.
The Victorian College of the Arts (VCA) is the arts school at the University of Melbourne in Australia. It is part of the university's Faculty of Fine Arts and Music (FFAM). It is located near the Melbourne city centre on the Southbank campus of the university. The VCA Film and Television School was founded in 1991, after it assumed ownership and management of the Swinburne Film and Television School. Courses and training offered at the VCA cover seventeen discipline areas: acting and theatre, composition, creative arts and music therapy, dance, design and production, ethnomusicology, film and television, Indigenous arts and culture, interactive composition, jazz and improvisation, music performance, music psychology, music theatre, musicology, performance teaching, visual art, and writing. The VCA is also home to the Wilin Centre for Indigenous Arts and Cultural Development. The library on the Southbank campus is known as the Lenton Parr Music, Visual and Performing Arts Library.
Sources: en.wikipedia.org
== Unbinding == Substrate unbinding is influenced by various factors. Larger ligands generally stay in the active site longer, as do those with more rotatable bonds (although this may be a side effect of size). When the solvent is excluded from the active site, less flexible proteins result in longer residence times. More hydrogen bonds shielded from the solvent also decrease unbinding.
As much as they tried, Cech and his colleagues could not identify any protein associated with the splicing reaction. After much work, Cech proposed that the intron sequence portion of the RNA could break and reform phosphodiester bonds. At about the same time, Sidney Altman, a professor at Yale University, was studying the way tRNA molecules are processed in the cell when he and his colleagues isolated an enzyme called RNase-P, which is responsible for conversion of a precursor tRNA into the active tRNA. Much to their surprise, they found that RNase-P contained RNA in addition to protein and that RNA was an essential component of the active enzyme. This was such a foreign idea that they had difficulty publishing their findings. The following year, Altman demonstrated that RNA can act as a catalyst by showing that the RNase-P RNA subunit could catalyze the cleavage of precursor tRNA into active tRNA in the absence of any protein component. Since Cech's and Altman's discovery, other investigators have discovered other examples of self-cleaving RNA or catalytic RNA molecules. Many ribozymes have either a hairpin – or hammerhead – shaped active center and a unique secondary structure that allows them to cleave other RNA molecules at specific sequences. It is now possible to make ribozymes that will specifically cleave any RNA molecule. These RNA catalysts may have pharmaceutical applications. For example, a ribozyme has been designed to cleave the RNA of HIV.
North Korea's human rights record is often considered to be the worst in the world and has been globally condemned, with the United Nations, the European Union and groups such as Human Rights Watch all critical of the country's record. Furthermore, North Korea has the highest estimated prevalence of modern slavery in the world. . As of 2021, a Global Slavery Index 2023 report estimates that about one-in-ten people live in modern slavery conditions. Forms of torture, forced labour, and abuses are all widespread. Most international human rights organizations consider North Korea to have no contemporary parallel with respect to violations of liberty.
According to the International Society for Plastination, the Epoxy E 12 procedure is used "for thin, transparent, and firm body and organ slices", while the Polyester P 35 (P 40) preserves "semitransparent and firm brain slices". Samples are prepared for fixation through the first method by deep freezing, while the second method works best following 4–6 weeks of preparation in a formaldehyde mixture.
Sources: en.wikipedia.org
==== Seed oil ==== Mature seeds yield 38–40% edible oil called ben oil from its high concentration of behenic acid. The refined oil is clear and odorless, and resists rancidity. The young fruits can be boiled and the oil skimmed off the water surface. The seed cake remaining after oil extraction may be used as a fertilizer or as a flocculent to purify water. Moringa seed oil also has potential for use as a biofuel.
=== Minimum wage === As a candidate for governor, Pritzker campaigned on raising the minimum wage in Illinois to $15 an hour. He enacted a plan to do so, raising the minimum wage to $9.25 an hour on January 1, 2020, and then to $10 an hour on July 1 of that year. The minimum wage has risen by $1 per hour each year on January 1. It was $15 as of January 1, 2025.
=== Adrenomedullin receptor === CALCRL binds Ramp2 to form the adrenomedullin receptor 1 (AM1), while it binds Ramp3 to form adrenomedullin receptor 2 (AM2). Adrenomedullin is a multifunctional 52 amino acid peptide widely expressed throughout the body. Its most prominent functions include regulation of blood pressure, endothelial barrier development and stability, and inflammation. Administration of adrenomedullin causes vasodilation and decreased blood pressure via binding to its receptors.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.